Valneva: EMA marketing authorization application for co-developed Lyme vax candidate with Pfizer
Valneva announces that the European Medicines Agency has validated the marketing authorization application for its co-developed Lyme disease vaccine candidate with Pfizer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.